Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 19, 2023 - Issue 1
Submit an article Journal homepage
1,746
Views
0
CrossRef citations to date
0
Altmetric
Vaccine Safety

Clinical trials show similar safety outcomes including febrile convulsion rates for GSK’s and Merck’s measles-mumps-rubella (MMR) vaccines

Md Ahsan Habiba Clinical Sciences, Live Viral Vaccines, GSK, Wavre, BelgiumCorrespondence[email protected]
View further author information
,
Michael Poveyb Vaccines Biostats, GSK, Wavre, BelgiumView further author information
,
Giacomo Casabonac Global Medical Affairs, GSK, Wavre, BelgiumView further author information
,
Tina Singhd Global Safety, GSK, Wavre, BelgiumView further author information
&
Remon Abu-Elyazeede Medical Affairs, GSK, Philadelphia, PA, USAView further author information
Article: 2188852 | Received 14 Sep 2022, Accepted 06 Mar 2023, Published online: 29 Mar 2023

References

  • Merck. M-M-R II. Product monograph. [accessed 2022 Jul 13]. https://www.merck.ca/en/wp-content/uploads/sites/20/2021/04/MMR_II-PM_E.pdf.
  • Abu-Elyazeed R. Overview of GSK’s MMR vaccine. ACIP meeting; 2022 Feb 23 [accessed 2022 June 24]. https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2022-02-23-24/02-mmr-abu-elyazeed-508.pdf.
  • M-M-R II Package Insert. [accessed 2022 Jun 24]. https://www.fda.gov/media/75191/download.
  • Priorix Package Insert. [accessed 2022 Jun 24]. https://www.fda.gov/media/158941/download.
  • News A. CDC vaccine group OKs new MMR, PCV vaccines for children. [accessed 2022 Jul 28]. https://publications.aap.org/aapnews/news/20686/CDC-vaccine-group-OKs-new-MMR-PCV-vaccines-for?autologincheck=redirected.
  • McLean HQ, Fiebelkorn AP, Temte JL, Wallace GS, Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR–04):1–5.
  • Leung AK, Hon KL, Leung TN. Febrile seizures: an overview. Drugs Context. 2018;7:212536. doi:10.7573/dic.212536.
  • Di Pietrantonj C, Rivetti A, Marchione P, Debalini MG, Demicheli V. Vaccines for measles, mumps, rubella, and varicella in children. Cochrane Database Syst Rev. 2021;11:CD004407. doi:10.1002/14651858.CD004407.pub5.
  • Mufson MA, Diaz C, Leonardi M, Harrison CJ, Grogg S, Carbayo A, Carlo-Torres S, JeanFreau R, Quintero-Del-Rio A, Bautista G, et al. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months. J Pediatric Infect Dis Soc. 2015;4(4):339–48. doi:10.1093/jpids/piu081.
  • Berry AA, Abu-Elyazeed R, Diaz-Perez C, Mufson MA, Harrison CJ, Leonardi M, Twiggs JD, Peltier C, Grogg S, Carbayo A, et al. Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin. Hum Vaccin Immunother. 2017;13(7):1516–22. doi:10.1080/21645515.2017.1309486.
  • Klein NP, Abu-Elyazeed R, Povey M, Macias Parra M, Diez-Domingo J, Ahonen A, Korhonen T, Tinoco JC, Weiner L, Marshall GS, et al. Immunogenicity and Safety of a Measles-Mumps-Rubella Vaccine Administered as a First Dose to Children Aged 12 to 15 Months: A Phase III, Randomized, Noninferiority, Lot-to-Lot Consistency Study. J Pediatric Infect Dis Soc. 2020;9(2):194–201. doi:10.1093/jpids/piz010.
  • MMR-161 Study Group. Immunogenicity and safety of measles-mumps-rubella vaccine at two different potency levels administered to healthy children aged 12–15 months: a phase III, randomized, non-inferiority trial. Vaccine. 2018;36(38):5781–88. doi:10.1016/j.vaccine.2018.07.076.
  • MMR-162 Study Group. Safety and immunogenicity of an upper-range release titer measles-mumps-rubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. Hum Vaccin Immunother. 2018;14(12):2921–31. doi:10.1080/21645515.2018.1502527.
  • MMR-158 Study Group. A second dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity study comparing GSK MMR and MMR II with and without DTaP-IPV and varicella vaccines co-administration. Hum Vaccin Immunother. 2019;15(4):786–99. doi:10.1080/21645515.2018.1554971.
  • Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study. Hum Vaccin Immunother. 2018;14(11):2624–31. doi:10.1080/21645515.2018.1489186.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.